Liraglutide

DEA Class; Rx

Common Brand Names; Victoza, Saxenda

Hypersensitivity to liraglutide or its components

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)

Saxenda only: Pregnancy

• Nausea (26%)
• Diarrhea (17%)
• Vomiting (11%)
• Nausea (39.3%)
• Hypoglycemia in T2DM (23%)
• Diarrhea (20.9%)
• Constipation (19.4%)
• Vomiting (15.7%)
• Headache (13.6%)
• Constipation (10%)
• Headache (9%)
• Antiliraglutide antibodies (7%)
• Injection-site reactions (2%)
• Decreased appetite (10%)
• Dyspepsia (9.6%)
• Fatigue (7.5%)
• Dizziness (6.9%)
• Abdominal pain (5.4%)
• Increased lipase (5.3%)
• Upper abdominal pain (5.1%)
• Gastroesophageal reflux disease (4.7%)
• Gastroenteritis (4.7%)
• Abdominal distension (4.5%)
• Eructation (4.5%)
• Urinary tract infection (4.3%)
• Flatulence (4%)
• Viral gastroenteritis (2.8%)
• Injection site erythema (2.5%)
• Injection site reaction (2.5%)
• Insomnia (2.4%)
• Dry mouth (2.3%)
• Asthenia (2.1%)
• Anxiety (2%)
• Urticaria
• Upper respiratory tract infection
• UTI
• Dizziness
• Sinusitis
• Nasopharyngitis
• Back pain
• Hypertension
• Hypoglycemia (mostly in combination therapy)
• Pancreatitis
• Papillary thyroid carcinoma
• Thyroid C-cell hyperplasia

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed; studied in a limited number of patients with a history of pancreatitis; unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis

Acute events of gallbladder disease such as cholelithiasis or cholecystitis reported in GLP-1 receptor agonist trials and postmarketing; if cholelithiasis suspected, gallbladder studies and appropriate clinical follow-up indicated

May cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and/or carcinomas) at clinically relevant exposures in both genders of rats and mice; if serum calcitonin is elevated, evaluate further; patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated

Renal Impairment reported in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis; altered renal function has been reversed in many of reported cases with supportive treatment and discontinuation of potentially causative agents; use caution when initiating or escalating doses of in these patients

There have been postmarketing reports of serious hypersensitivity reactions (eg, anaphylactic reactions, angioedema)

Never share pen between patients even if needle is changed

Victoza

• Based on animal reproduction studies, there may be risks to the fetus from exposure during pregnancy
• Use during pregnancy only if the potential benefit justifies the potential risk to the fetus

Saxenda

• Contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm
• There are no available data in pregnant women to inform a drug associated risk for major birth defects and miscarriage

There are no data on the presence of drug in human milk, the effects on the breastfed infant, or the effects on milk production